REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Celldex is developing targeted therapeutics to address devastating diseases for wh...
Celldex is developing targeted therapeutics to ...
Cidara is a clinical-stage biotechnology company focused on the discovery, develop...
Cidara is a clinical-stage biotechnology compan...
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...
Mersana Therapeutics is a clinical-stage biopha...
SelenBio, Inc is a biotechnology company specializing in the prevention of bacteri...
SelenBio, Inc is a biotechnology company specia...
Cidara is a clinical-stage biotechnology company focused on the discovery, develop...
Cidara is a clinical-stage biotechnology compan...
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device compan...
Cardiovascular Systems, Inc., based in St. Paul...
IVERIC bio is a gene therapy focused company developing innovative treatments for ...
IVERIC bio is a gene therapy focused company de...
Join the National Investor Network and get the latest information with your interests in mind.